Molecular Health GuideTM Workbench Manager for comprehensive, end-to-end clinical decision support
Molecular Health GuideTM Clinical Annotation Service for variant analysis and interpretation
BOSTON and HEIDELBERG, Germany, Nov. 07, 2016 (GLOBE NEWSWIRE) — Molecular Health, a leader in decision support technology for precision medicine, today announced the launch of its next-generation clinical decision support solutions, Molecular Health GuideTM Workbench Manager and Molecular Health GuideTM Clinical Annotation Service. These services are based on the Company’s proprietary cloud-based software platform for the automated analysis, clinical interpretation, and reporting of genetic alterations from next-generation sequencing (NGS) performed by laboratories and hospitals. Molecular Health will be showcasing the new Molecular Health GuideTM offerings, initially provided in oncology, at Booth #1805 during the Association for Molecular Pathology (AMP) 2016 Annual Meeting taking place November 10-12 at the Charlotte Convention Center in North Carolina.
These new clinical decision support products are based on Molecular Health’s DataomeTM technology, which focuses on the capture, integration, and analysis of molecular outcomes data from patients that are mapped to expert-curated, peer-reviewed, published biomedical literature. The curated databases include clinical variant interpretations (CVIs) that are created by a rigorous process that includes expert physician review.
Molecular Health GuideTM Workbench Manager delivers a comprehensive clinical decision support service, from bioinformatics analysis of the NGS data from a patient’s tumor to the generation of a custom report. Based upon the identification of reportable variants, Workbench Manager generates a summary of potentially effective treatment options, potentially ineffective treatment options, and treatment options that may pose a higher risk of adverse reactions. It also provides a matching tool for clinical trials. Workbench Manager enables physicians and laboratories to reduce the time-consuming, cost-intensive and error-prone process of manual variant interpretation by providing clinical annotations and interpretations reviewed by expert molecular pathologists and oncologists. Workbench Manager features a rich, interactive user interface and digital workflow for those who want to create a high-quality tailored report available in minutes.
Molecular Health GuideTM Clinical Annotation Service powers the automated delivery of clinically-reviewed annotations for actionable variants. Within minutes, Clinical Annotation Service delivers client customized clinically-relevant data, including: clinical variant narratives, evidence-based treatment options, matching trials, and other supplemental data such as drug descriptions and relevant drug-drug interactions. The technology is highly scalable and easily integrated into existing workflows, pipeline management, and reporting systems for use by high-throughput laboratories and other high-volume customers.
Les Paul, MD, MS, Chief Medical Officer and U.S. CEO, Molecular Health, commented, “Molecular Health GuideTM clinical decision support solutions help molecular pathologists and oncologists to more effectively manage molecular information from Next-Generation Sequencing of patients’ tumors including the identification of potentially effective or potentially ineffective treatment and relevant clinical trials. We have designed these offerings to strategically address the needs of oncologists and pathologists as well as large laboratory, hospital, and research customers.”
Friedrich von Bohlen, Chief Executive Officer, Molecular Health, commented, “Molecular Health is the leading precision medicine and clinical decision support option for customers who want access to make more informed treatment decisions. We developed both Molecular Health GuideTM offerings based on the valuable input of the medical community and now we have a product that is primed to improve patient care and outcomes by empowering the medical community with access to real-time solutions which leverage the world’s healthcare data. The breadth and quality of our contributions to the medical community are exemplified with this product launch and our recent Clinical Laboratory Improvement Amendments (CLIA) certification and College of American Pathologists (CAP) accreditation for bioinformatics analysis, variant annotation and interpretation. This launch executes on our mission to power the future of precision medicine.”
Molecular Health GmbH is certified according to DIN EN ISO 13485 for the design, development and manufacture of software systems for the integrated analysis of clinical and genomic patient data to support treatment decisions and provision of related services. In addition, Molecular Health is Clinical Laboratory Improvement Amendments (CLIA) certified and accredited by the College of American Pathologists (CAP) for bioinformatics analysis, variant annotation and interpretation. This allows Molecular Health to provide its bioinformatics analysis services to clinical laboratories in the United States that are also accredited.
In the European Union, Molecular Health GuideTM is registered as an In Vitro Diagnostic (IVD) device.
About Molecular Health
Molecular Health is a leading precision medicine informatics company that leverages its proprietary cloud-based DataomeTM technology platform to provide a comprehensive and disruptive healthcare decision engine. The DataomeTM technology platform is the culmination of carefully curated and medically-reviewed information from millions of scientific and medical publications together with data from globally available databases of clinical and molecular information. The platform is regularly updated and curated by biomedical experts along strict processes, and has robust and expanding IP protection. DataomeTM technology powers the Company’s Molecular Health GuideTM service offerings.
Molecular Health GmbH is located in Heidelberg, Germany and its subsidiary, Molecular Health, Inc., is located in Boston, Massachusetts, USA.
To learn more, please visit: www.molecularhealth.com.
CONTACT: Investors Nick Laudico The Ruth Group (646) 536-7030 email@example.com Media Kirsten Thomas / Chris Hippolyte The Ruth Group +1 508-280-6592 / +1 646-536-7023 firstname.lastname@example.org / email@example.com